Novartis secures injunction barring generic MS drugs

26-06-2019

Novartis secures injunction barring generic MS drugs

Lucarista / Shutterstock.com

A US court has issued an injunction barring the manufacture of generic versions of Swiss pharmaceutical company Novartis’ multiple sclerosis (MS) drug Gileyna (fingolimod).


Novartis, Gileyna, fingolimod, multiple sclerosis, RRMS, MS, Mylan, Dr. Reddys, Teva, injunction

LSIPR